{"frequencyBands":{"HP:0040280":[100,100],"HP:0040281":[80,99],"HP:0040282":[30,79],"HP:0040283":[5,29],"HP:0040284":[1,4],"HP:0040285":[0,0]},"page":{"anchorSlug":"neuronal-ceroid-lipofuscinosis-11","columns":[{"countQualifier":"Onset group unspecified","gene":"GRN","key":"population-bde6a4a53ea97021e60a","label":"CLN11","mondoId":"MONDO:0013866","onsetQualifier":null,"originColumnKey":"MONDO:0013866","originalViews":[{"key":"MONDO:0013866","label":"CLN11","scopeLabel":"Genetic form","sourceScope":null}],"recordKeys":["36adbcf967be7851873919742b747be63a4a80d66c8faae41d9bfcef86bf7766","3ea7edfc608bf9fa3d5e7e8e15efb251dfcc476a7a7e74508c37126d5296f631","4db35379982fd1e51ceb2f877bb5390587b3e7cc4cf3868d70a7c5515dae7923","7afd6eec3e7bca3f8c45a3040d33bab5e6fd52b5b6015760f07f62ada468b205","7fd6dde8dbaeb1c347480dc39024b7fc6a8304d6c2f2e86727ce5119173a195f","a9b60fea329ee02a3113fbccd861a5c38dd5feecaab9c410754756642e9f9798","ba37d0c280935f826e883fe942f7bd4b559c57d1d3961fe24637f221f447544e","bea8e16b332db73dbe7ee35185edad82800fddafd24c234f806edd7b0b911b60","c9920f4a687d098c3722a271827b97eb4c1bb7f8cd3f7d6948a8edc475014e14","fc8c443040a36cde34a17a0ee281c400e036ede1ca6367ad96ff2b9632dc2d19"],"recordQualifiers":{"3ea7edfc608bf9fa3d5e7e8e15efb251dfcc476a7a7e74508c37126d5296f631":"Onset group unspecified","4db35379982fd1e51ceb2f877bb5390587b3e7cc4cf3868d70a7c5515dae7923":"Onset group unspecified","7afd6eec3e7bca3f8c45a3040d33bab5e6fd52b5b6015760f07f62ada468b205":"Onset group unspecified","7fd6dde8dbaeb1c347480dc39024b7fc6a8304d6c2f2e86727ce5119173a195f":"Onset group unspecified","a9b60fea329ee02a3113fbccd861a5c38dd5feecaab9c410754756642e9f9798":"Onset group unspecified","ba37d0c280935f826e883fe942f7bd4b559c57d1d3961fe24637f221f447544e":"Onset group unspecified","bea8e16b332db73dbe7ee35185edad82800fddafd24c234f806edd7b0b911b60":"Onset group unspecified","c9920f4a687d098c3722a271827b97eb4c1bb7f8cd3f7d6948a8edc475014e14":"Onset group unspecified","fc8c443040a36cde34a17a0ee281c400e036ede1ca6367ad96ff2b9632dc2d19":"Onset group unspecified"},"scopeLabel":"Genetic form","sourceIds":["OMIM:614706"],"sourceScope":null}],"comparison":{"collapseColumnsLabel":"Show default populations","defaultColumnKeys":["population-bde6a4a53ea97021e60a"],"expandColumnsLabel":"Show all source populations","intro":"Features recorded for this MONDO node. Related-node evidence is available through separately scoped comparisons.","primaryFeatureIds":["HP:0001251","HP:0001272","HP:6001187","HP:0012001","HP:0002123","HP:0001268","HP:0000648"],"scopeNoteHtml":"<p>Each column retains its native condition identifier, assessed population and annotation references. Counts are not pooled.</p>"},"coverage":{"countRecords":9,"emptyColumnKeys":[],"hpoRelease":"2026-06-23","narrativeSourceChanges":[],"records":10,"sourceGroups":{"published":10}},"features":[{"hpoId":"HP:0001251","label":"Ataxia","primary":true},{"hpoId":"HP:0001272","label":"Cerebellar atrophy","primary":true},{"hpoId":"HP:6001187","label":"Decreased circulating progranulin concentration","primary":true},{"hpoId":"HP:0012001","label":"EEG with generalized polyspikes","primary":true},{"hpoId":"HP:0002123","label":"Generalized myoclonic seizure","primary":true},{"hpoId":"HP:0001268","label":"Mental deterioration","primary":true},{"hpoId":"HP:0000648","label":"Optic atrophy","primary":true},{"hpoId":"HP:0000556","label":"Retinal dystrophy","primary":false},{"hpoId":"HP:0001250","label":"Seizure","primary":false},{"hpoId":"HP:0000505","label":"Visual impairment","primary":false}],"ledeHtml":"CLN11 disease is a disorder that primarily affects the nervous system. Individuals with this condition typically show signs and symptoms in adolescence or early adulthood. This condition is characterized by recurrent seizures (epilepsy), vision loss, problems with balance and coordination (cerebellar ataxia), and a decline in intellectual function.","mondoId":"MONDO:0013866","node":{"canonicalSlug":"neuronal-ceroid-lipofuscinosis-11","comparisons":[{"documentSha256":"feab7132c1e6efa19316faa9c5b975a6a6317da700f12b5b4c059a18eda6d069","key":"legacy-cln","kind":"legacy","label":"CLN / Batten disease","memberIds":["MONDO:0008083","MONDO:0008767","MONDO:0008768","MONDO:0008769","MONDO:0009744","MONDO:0009745","MONDO:0010830","MONDO:0011144","MONDO:0012391","MONDO:0012414","MONDO:0012588","MONDO:0012721","MONDO:0013866","MONDO:0014147","MONDO:0016295"],"mondoId":"MONDO:0016295","url":"https://kcjyutqgtpgteszueluf.supabase.co/storage/v1/object/public/community-guides/learn-data/cln.feab7132c1e6efa19316faa9c5b975a6a6317da700f12b5b4c059a18eda6d069.json"},{"documentSha256":"df7e5010cb40de30aba1b0d10ff00b9c8a49865234f6a0ea186c9a1493e9aae3","key":"expanded-cln","kind":"expanded","label":"CLN / Batten disease","memberIds":["MONDO:0008083","MONDO:0008767","MONDO:0008768","MONDO:0008769","MONDO:0009744","MONDO:0009745","MONDO:0010830","MONDO:0011144","MONDO:0012188","MONDO:0012391","MONDO:0012414","MONDO:0012588","MONDO:0012721","MONDO:0013866","MONDO:0014147","MONDO:0016295","MONDO:0017809","MONDO:0019260","MONDO:0019261","MONDO:0019262","MONDO:0030947","MONDO:0850001"],"mondoId":"MONDO:0016295","url":"https://kcjyutqgtpgteszueluf.supabase.co/storage/v1/object/public/community-guides/learn-data/node-comparison-df7e5010cb40de30aba1.df7e5010cb40de30aba1b0d10ff00b9c8a49865234f6a0ea186c9a1493e9aae3.json"}],"contexts":[],"lifecycle":"active","narrative":{"causes":["CLN11 disease results from mutations in the GRN gene. This gene provides instructions for making a protein called progranulin. Progranulin is active in many different tissues in the body, where it helps control the growth, division, and survival of cells. Progranulin's function in the brain is not well understood, although it appears to play an important role in the survival of nerve cells (neurons).","GRN gene mutations that cause CLN11 disease result in a complete loss of functional progranulin protein. This lack of progranulin causes the death of nerve cells in the brain, although the exact mechanism is unknown. Widespread loss of neurons in CLN11 disease leads to the development of signs and symptoms in adolescence or early adulthood."],"causesUrl":"https://medlineplus.gov/genetics/condition/cln11-disease/#causes","contentForm":"summary","matchMethod":"reviewed-binding","name":"CLN11 disease","paragraphs":["CLN11 disease is a disorder that primarily affects the nervous system. Individuals with this condition typically show signs and symptoms in adolescence or early adulthood. This condition is characterized by recurrent seizures (epilepsy), vision loss, problems with balance and coordination (cerebellar ataxia), and a decline in intellectual function.","Seizures in CLN11 disease often involve a loss of consciousness, muscle stiffness (rigidity), and generalized convulsions (tonic-clonic seizures).","Vision loss is gradual over time and is due to a condition called retinitis pigmentosa, which is caused by the breakdown of the light-sensitive layer at the back of the eye (retina). People with CLN11 disease can also develop clouding of the lenses of the eyes (cataracts) and rapid, involuntary eye movements (nystagmus).","Affected individuals can also develop muscle twitches (myoclonus), walking problems and falling (gait disturbance), and impaired speech (dysarthria). Over time, people with CLN11 disease develop short-term memory loss and loss of executive function, which is the ability to plan and implement problem-solving strategies and actions. They may also become irritable and impulsive. Some affected individuals experience visual hallucinations involving people or animals.","CLN11 disease is one of a group of disorders known as neuronal ceroid lipofuscinoses (NCLs). All of these disorders affect the nervous system and typically cause progressive problems with vision, movement, and thinking ability. The different NCLs are distinguished by their genetic cause. Each disease type is given the designation \"CLN,\" meaning ceroid lipofuscinosis, neuronal, and then a number to indicate its subtype."],"reviewed":"2020-04","scope":"exact","scopeNote":"","source":"MedlinePlus","sourceRelease":"2026-10-01","upstream":"MedlinePlus Genetics","url":"https://medlineplus.gov/genetics/condition/cln11-disease"},"ownColumnKeys":["population-bde6a4a53ea97021e60a"],"publication":"published","relationships":[{"kind":"parent","label":"adult neuronal ceroid lipofuscinosis","mondoId":"MONDO:0019260","slug":"adult-neuronal-ceroid-lipofuscinosis"}],"schemaVersion":1,"searchIndex":"/node-search/manifest.json","sourceHolds":{},"summaryHolds":[{"reason":"native-cross-reference-does-not-establish-scope","source":"MedlinePlus","url":"https://medlineplus.gov/genetics/condition/cln11-disease"},{"reason":"Public source record is not available in the frozen inputs","source":"GARD","url":"https://rarediseases.info.nih.gov/diseases/17426"}],"translation":"published"},"records":[{"frequencyKind":"reported","key":"36adbcf967be7851873919742b747be63a4a80d66c8faae41d9bfcef86bf7766","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:614706","disease_name":"Ceroid lipofuscinosis, neuronal, 11","evidence":"PCS","frequency_raw":null,"hpo_id":"HP:6001187","is_excluded":false,"label":"Decreased circulating progranulin concentration","onset_id":null,"reference":"PMID:29053785","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"3ea7edfc608bf9fa3d5e7e8e15efb251dfcc476a7a7e74508c37126d5296f631","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:614706","disease_name":"Ceroid lipofuscinosis, neuronal, 11","evidence":"PCS","frequency_raw":"1/2","hpo_id":"HP:0001272","is_excluded":false,"label":"Cerebellar atrophy","onset_id":null,"reference":"PMID:22608501","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"4db35379982fd1e51ceb2f877bb5390587b3e7cc4cf3868d70a7c5515dae7923","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:614706","disease_name":"Ceroid lipofuscinosis, neuronal, 11","evidence":"PCS","frequency_raw":"2/2","hpo_id":"HP:0012001","is_excluded":false,"label":"EEG with generalized polyspikes","onset_id":null,"reference":"PMID:22608501","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"7afd6eec3e7bca3f8c45a3040d33bab5e6fd52b5b6015760f07f62ada468b205","raw":{"aspect":"P","body_system":"eye","disease_id":"OMIM:614706","disease_name":"Ceroid lipofuscinosis, neuronal, 11","evidence":"PCS","frequency_raw":"2/2","hpo_id":"HP:0000505","is_excluded":false,"label":"Visual impairment","onset_id":null,"reference":"PMID:22608501","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"7fd6dde8dbaeb1c347480dc39024b7fc6a8304d6c2f2e86727ce5119173a195f","raw":{"aspect":"P","body_system":"eye","disease_id":"OMIM:614706","disease_name":"Ceroid lipofuscinosis, neuronal, 11","evidence":"PCS","frequency_raw":"1/1","hpo_id":"HP:0000648","is_excluded":false,"label":"Optic atrophy","onset_id":null,"reference":"PMID:22608501","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"a9b60fea329ee02a3113fbccd861a5c38dd5feecaab9c410754756642e9f9798","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:614706","disease_name":"Ceroid lipofuscinosis, neuronal, 11","evidence":"PCS","frequency_raw":"2/2","hpo_id":"HP:0001250","is_excluded":false,"label":"Seizure","onset_id":null,"reference":"PMID:22608501","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"ba37d0c280935f826e883fe942f7bd4b559c57d1d3961fe24637f221f447544e","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:614706","disease_name":"Ceroid lipofuscinosis, neuronal, 11","evidence":"PCS","frequency_raw":"1/2","hpo_id":"HP:0002123","is_excluded":false,"label":"Generalized myoclonic seizure","onset_id":null,"reference":"PMID:22608501","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"bea8e16b332db73dbe7ee35185edad82800fddafd24c234f806edd7b0b911b60","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:614706","disease_name":"Ceroid lipofuscinosis, neuronal, 11","evidence":"PCS","frequency_raw":"1/2","hpo_id":"HP:0001268","is_excluded":false,"label":"Mental deterioration","onset_id":null,"reference":"PMID:22608501","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"c9920f4a687d098c3722a271827b97eb4c1bb7f8cd3f7d6948a8edc475014e14","raw":{"aspect":"P","body_system":"eye","disease_id":"OMIM:614706","disease_name":"Ceroid lipofuscinosis, neuronal, 11","evidence":"PCS","frequency_raw":"1/2","hpo_id":"HP:0000556","is_excluded":false,"label":"Retinal dystrophy","onset_id":null,"reference":"PMID:22608501","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"fc8c443040a36cde34a17a0ee281c400e036ede1ca6367ad96ff2b9632dc2d19","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:614706","disease_name":"Ceroid lipofuscinosis, neuronal, 11","evidence":"PCS","frequency_raw":"2/2","hpo_id":"HP:0001251","is_excluded":false,"label":"Ataxia","onset_id":null,"reference":"PMID:22608501","source_release":"2026-06-23"},"sourceGroups":["published"]}],"referenceLabels":{},"references":{"causeHtml":"<p class=\"section-source\">Source: <a href=\"https://medlineplus.gov/genetics/condition/cln11-disease\" rel=\"noreferrer\">MedlinePlus</a></p><p class=\"section-source\">Source: <a href=\"https://monarchinitiative.org/MONDO:0013866\" rel=\"noreferrer\">MONDO</a></p><details class=\"deep-dive\"><summary>Narrative source and scope</summary><dl><dt>Content</dt><dd>summary</dd><dt>Scope</dt><dd>exact</dd><dt>Match method</dt><dd>reviewed-binding</dd><dt>Upstream attribution</dt><dd>MedlinePlus Genetics</dd></dl></details>","identityNote":"MONDO identifies this node. Native source populations, annotation references and qualified comparison views retain their original scopes.","importantHtml":""},"sections":[{"bodyHtml":"<p>CLN11 disease is a disorder that primarily affects the nervous system. Individuals with this condition typically show signs and symptoms in adolescence or early adulthood. This condition is characterized by recurrent seizures (epilepsy), vision loss, problems with balance and coordination (cerebellar ataxia), and a decline in intellectual function.</p><p>Seizures in CLN11 disease often involve a loss of consciousness, muscle stiffness (rigidity), and generalized convulsions (tonic-clonic seizures).</p><p>Vision loss is gradual over time and is due to a condition called retinitis pigmentosa, which is caused by the breakdown of the light-sensitive layer at the back of the eye (retina). People with CLN11 disease can also develop clouding of the lenses of the eyes (cataracts) and rapid, involuntary eye movements (nystagmus).</p><p>Affected individuals can also develop muscle twitches (myoclonus), walking problems and falling (gait disturbance), and impaired speech (dysarthria). Over time, people with CLN11 disease develop short-term memory loss and loss of executive function, which is the ability to plan and implement problem-solving strategies and actions. They may also become irritable and impulsive. Some affected individuals experience visual hallucinations involving people or animals.</p><p>CLN11 disease is one of a group of disorders known as neuronal ceroid lipofuscinoses (NCLs). All of these disorders affect the nervous system and typically cause progressive problems with vision, movement, and thinking ability. The different NCLs are distinguished by their genetic cause. Each disease type is given the designation &quot;CLN,&quot; meaning ceroid lipofuscinosis, neuronal, and then a number to indicate its subtype.</p><p class=\"section-source\">Source: <a href=\"https://medlineplus.gov/genetics/condition/cln11-disease\" rel=\"noreferrer\">MedlinePlus</a></p>","key":"overview","title":"Overview"},{"bodyHtml":"<p>CLN11 disease results from mutations in the GRN gene. This gene provides instructions for making a protein called progranulin. Progranulin is active in many different tissues in the body, where it helps control the growth, division, and survival of cells. Progranulin&#x27;s function in the brain is not well understood, although it appears to play an important role in the survival of nerve cells (neurons).</p><p>GRN gene mutations that cause CLN11 disease result in a complete loss of functional progranulin protein. This lack of progranulin causes the death of nerve cells in the brain, although the exact mechanism is unknown. Widespread loss of neurons in CLN11 disease leads to the development of signs and symptoms in adolescence or early adulthood.</p><p class=\"section-source\">Source: <a href=\"https://medlineplus.gov/genetics/condition/cln11-disease/#causes\" rel=\"noreferrer\">MedlinePlus</a></p>","key":"causes","title":"Causes"}],"sharedSources":[],"slug":"neuronal-ceroid-lipofuscinosis-11","sourceDocuments":[{"name":"MedlinePlus: CLN11 disease","reviewed":"2020-04","source_release":"2026-10-01","url":"https://medlineplus.gov/genetics/condition/cln11-disease"},{"name":"MONDO: neuronal ceroid lipofuscinosis 11","reviewed":null,"source_release":"releases/2026-10-06","url":"https://monarchinitiative.org/MONDO:0013866"}],"sourceNote":"","synonyms":["ceroid lipofuscinosis, neuronal, 11","ceroid lipofuscinosis, neuronal, type 11","CLN11","GRN neuronal ceroid lipofuscinosis","Grn neuronal ceroid lipofuscinosis","neuronal ceroid lipofuscinosis caused by mutation in GRN","neuronal ceroid lipofuscinosis caused by mutation in Grn","neuronal ceroid lipofuscinosis type 11"],"takeawayHtml":"","title":"neuronal ceroid lipofuscinosis 11"},"schemaVersion":1}
